Dr. Brammer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-7526
Education & Training
- Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2012 - 2015
- Baylor College of MedicineResidency, Internal Medicine, 2009 - 2012
- Northeast Ohio Medical UniversityClass of 2009
Certifications & Licensure
- OR State Medical License 2012 - Present
- OH State Medical License 2016 - 2025
- TX State Medical License 2011 - 2019
Publications & Presentations
PubMed
- Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra
Leukemia & Lymphoma. 2025-01-01 - 1 citationsRepresentation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.Sujay Kalathoor, Sanam Ghazi, Beryl Otieno, Melissa A Babcook, Sunnia Chen
International Journal of Cancer. 2024-12-01 - Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.Zachary Braunstein, Jonathan E Brammer
Current Hematologic Malignancy Reports. 2024-12-01
Abstracts/Posters
- Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationJonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- New Three-Drug Combo Stimulates 'Master Cancer Killer' Cells, Boosts Immune System of Patients Undergoing Stem Cell TransplantationJanuary 3rd, 2022
- Duvelisib Tested in Rare Lymphoma SubtypeMarch 4th, 2020
- Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to GoJune 7th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: